Why Viking Therapeutics Stock Plummeted by 24% in December

Viking Therapeutics (NASDAQ: VKTX) didn’t exactly capture investors’ hearts in the final month of 2024. In mid-December, Merck announced it had entered into a licensing deal with China-based biotech Hansoh Pharma for that company’s investigational weight-loss drug. If developed successfully, the drug, labeled HS-10535, would surely pose a serious threat to Viking’s No. 1 pipeline program, VK2735.

This article was originally published here.